0 Pro · 1 Con
The FDA's 2024 rejection was based on trial-design concerns, not evidence of harm. The solution is a clear licensing pathway with rigorous therapist certification requirements and supervised administration protocols — not continued prohibition of the most promising psychiatric drug class in 50 years.
Phase 2 MAPS trials showed 67% of MDMA-treated PTSD patients no longer met the diagnostic criteria at 12 months — a remission rate no existing treatment approaches. Psilocybin trials at Johns Hopkins and NYU show comparable results for treatment-resistant depression. For conditions that have defeated every available treatment, the evidence base is remarkable.
The most rigorous MDMA trial the FDA reviewed in 2024 failed to beat placebo in one of two Phase 3 studies. The blinding problem is severe: participants almost always know they took the drug, making expectancy effects inseparable from pharmacological ones. The effect size may be mostly placebo amplified by intense therapeutic context.
Psychedelics carry real risks: triggering latent psychosis, cardiac events with MDMA, and serious ethical violations in therapeutic contexts. Three therapists in MAPS's own trials were found to have sexually abused patients during or after sessions. The vulnerability of people in altered states creates abuse risks that are not hypothetical.
The set, setting, and therapeutic relationship appear to drive most of the effect. The commercialization model — brief drug administration with minimal therapy — strips out what actually works while profiting from the brand. That approach serves investors at the expense of patient safety and treatment integrity.
Psilocybin mushrooms, peyote, and ayahuasca each have documented histories of safe ceremonial and therapeutic use spanning millennia. The unknown-risk framing applies to rapid pharmaceutical commercialization, not to the substances themselves. Safety profiles are better understood for these compounds than for many FDA-approved medications.
